Introduction

skingenix

Introduction

The non-clinical and clinical pharmacological studies for MEBO^® Wound Ointment (MEBO) contained in this website have been conducted independently from Skingenix, Inc. The scientific findings concerning the drug have been included mainly for the sole purpose of scientific information exchange and is not intended for marketing or promotional uses. This botanical drug MEBO has not been approved by the Food and Drug Administration for any indication of use in the United States. It is currently under the status of Investigational New Drug (Phase II) for patients with burn injuries, venous stasis ulcers and diabetic foot ulcers.

MEBO, a US patented botanical ointment has been approved and marketed in China since 1988. Currently, this drug product is also marketed in 24 countries worldwide.

Non-clinical pharmacological study results indicate that MEBO may have the following therapeutic properties:

Maintain wound in a physiological moist environment

Promote wound healing

Enhance quality of healing

Anti-shock in extensive burns

Improve wound microcirculation in the zone of stasis in the early stages after burns

Protect wound from potential infection

Modulate wound healing cytokines transformation with a characteristic expression pattern

Clinical pharmacological studies and clinical observations indicate that MEBO may have the following therapeutic properties:

Maintain wound in a physiological moist environment

Improve microcirculation in wounds

Ease of liquefying and discharging the necrotic tissues

Prevent wound from infection

Promote wound healing

Reduce pain during treatment

Improve quality of healing

Minimize scarring while significantly reducing medical care costs and providing better quality of life

The Skingenix, Inc. website has been designed for the audience worldwide. This website contains information about products which may or may not be available in different countries. In addition, the official approval or market clearance for indications of use may also differ per each country. Please consult individual country sites for approved uses and any applicable restrictions.The research data disclosed in this website is wholly for the purpose of scientific information exchange and is not intended for marketing or promotional uses.

Please note that Skingenix's drug product MEBO® Wound Ointment has not been approved by the Food and Drug Administration for any indication of use in the United States. It is currently under the status of Investigational New Drug (Phase II) for patients with burn injuries, venous stasis ulcers and diabetic foot ulcers.